4/A: Annovis Bio Director Amends Stock Ownership Report

Annovis Bio Director Michael B. Hoffman filed an amended Form 4 to correct reported beneficial ownership totals following multiple common stock purchases.

Summary

• Michael B. Hoffman, a Director of Annovis Bio, Inc. (ANVS), filed an amended Form 4/A.
• The amendment was filed to correct the total number of securities beneficially owned following reported transactions in the original Form 4.
• The original transactions, dated November 24, 2025, involved the acquisition of Annovis Bio Common Stock.
• Mr. Hoffman purchased a total of 39,200 shares across four separate transactions on November 24, 2025.
• The purchase prices ranged from $3.85 to $4.15 per share.
• Following these transactions, Mr. Hoffman directly beneficially owns 2,529,739 shares of Common Stock.
• Additionally, 223,357 shares are indirectly beneficially owned through The 2018 Jane and Michael Hoffman Descendants Trust, over which Mr. Hoffman has voting and investment power.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a company director increasing their stake through open market purchases, which typically signals confidence in the company's future performance.

Positives

• A company director, Michael B. Hoffman, increased his direct beneficial ownership by purchasing 39,200 shares of common stock, signaling confidence in the company's future prospects.
• The purchases were made at market prices ranging from $3.85 to $4.15 per share, indicating a personal investment at current valuations.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Management Comments

• "This Amendment to the Form 4 filed on November 25, 2025 is being filed to correct the totals shown in column 5 after each of the reported transactions. No other changes to the previously-reported transactions are being made."

Industry Context

Insider buying, such as the director's purchase of Annovis Bio shares, is often interpreted by the market as a positive signal, indicating that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This can sometimes lead to increased investor confidence in the short term.

Related Party Transactions

• Michael B. Hoffman indirectly beneficially owns 223,357 shares of Common Stock through The 2018 Jane and Michael Hoffman Descendants Trust, a family trust over which he has voting and investment power.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of management's confidence in the company's value and future prospects, potentially boosting investor sentiment.

Key Dates

Recommendation

The director's decision to purchase a significant number of shares at market prices suggests strong insider confidence in Annovis Bio's valuation and future outlook. This insider buying activity often precedes positive company developments and can be a compelling signal for investors to consider a 'buy' position, assuming other fundamental analyses align.

Keywords

Annovis Bio, ANVS, insider trading, Form 4, stock purchase, director, beneficial ownership, equity acquisition